Trial

Summary : AbbVie has terminated its collaboration agreement with BioArctic in the development of alpha-synuclein antibodies for Parkinson’s disease and other movement…

Summary : AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at…

Summary : Chicago-based AbbVie has been making major decisions with company-wide impacts. The therapeutic company appears to be making changes that will…

Summary : Moderna is poised to begin Phase III of its pivotal clinical trial for its candidate vaccine for respiratory syncytial virus…

Summary : At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business,…

Synopsis: GlaxoSmithKline has voluntarily paused activities in its Phase III GRACE trial on an experimental maternal vaccine for respiratory syncytial virus (RSV).…

Summary : The phase 3 trial involved over 800 candidates to assess ensifentrine when administered as a maintenance therapy to patients diagnosed…

Synopsis : Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, today…

Summary : Daiichi Sankyo Company, Limited announced that the first patient was dosed in the global DESTINY-Lung04 phase 3 trial evaluating the…

Synopsis: AbbVie’s blockbuster hopeful Rinvoq notched a win in a tricky-to-treat group of Crohn’s disease patients. The trial studied the AbbVie drug…